Researchers found that Libre users checked their glucose readings an average of 16 times a day; that’s about three times the amount of fingerstick checks that medical professionals recommend for people with Type 1 diabetes, according to Tim Dunn, an Abbott associate research fellow connected with the analysis. The Libre differs from a continuous glucose […]
Here are some tips for getting more test strips at a lower cost, either through insurance or by paying cash.
Novo Nordisk recently announced FDA approval of an expanded pediatric indication for Tresiba, meaning that the basal insulin can now be used to treat people with type 1 and type 2 diabetes as young as age one. The label update is based on data from the BEGIN YOUNG 1 trial, which showed Tresiba is safe […]
A study in Diabetes Care showed that patients with poorly controlled type 2 diabetes who received a combination of exenatide and pioglitazone had a threefold lower rate of hypoglycemia, a one-percentage-point greater reduction in A1C and less weight gain than those in the basal-bolus insulin therapy group.
Afrezza, invented by MannKind, a Connecticut-based pharmaceutical company, is the only inhalable insulin in existence. It’s actually been on the market once before. When it was first launched, about a decade ago, the apparatus to take the insulin was so giant and ill conceived that some likened it to a bong. The new inhaler is […]
We’ve been listening to earnings calls and talking with company execs, industry insiders and PR teams to get a sense of what else is on the horizon, compiled in the following report.
In September, the FDA approved the first hybrid closed-loop system for automating insulin delivery to reduce both highs and lows: Medtronic’s MiniMed 670G system including the latest Guardian Sensor 3 CGM. The milestone approval came after an unexpectedly fast three-month FDA review, and just four months after Medtronic reported positive data from its three-month home […]
A new Bluetooth insulin dose tracker, called Insulog, can be fitted onto most existing insulin pens to prevent dose errors in people with type 1 diabetes and insulin-treated type 2 diabetes. The device, created by a Tel Aviv-based startup, is the object of an online crowdfunding campaign recently launched on Indiegogo.
Perception of “hassle” is the most common modifiable barrier keeping people with type 1 diabetes from choosing to wear insulin pumps and continuous glucose monitors (CGMs), new research indicates.
We’ve rounded up descriptions of some of the most exciting diabetes products expected to hit the market in 2017, followed by an approximate timeframe of when they’ll become available to the public. Sure, what we really want is a cure in 2017, but we’ll take improved quality of life, thanks to new devices and tech, […]
We reported earlier this week about a landmark roundtable gathering of diabetes advocates and industry leaders in Washington D.C. to address the complex problem of insulin affordability and access here in the U.S.
PBMs are organizations commonly understood to be the “middle men” in the chain of distribution of prescription drugs and medical devices from the manufacturers to the places where those products are dispensed or purchased through an insurance carrier or a prescription purchase plan. They are also considered the organizations to which health insurance carriers outsource […]
Earlier this month, Dexcom shared compelling new details on its longer-wear, less calibration G6 sensor and its partnership with Verily to develop a bandage-like continuous glucose monitoring (CGM) device. The G6 sensor is expected to launch in 2018, while the first-gen Verily sensor will launch in late 2018, with a second-gen version coming as early […]
The maker of inhaled insulin Afrezza is betting that relaunching their product and making it a success depends less on diabetics being afraid of needles and more on its clinical advantages over existing insulin.
Many in the Type 1 diabetes community wish for two things: lower insulin prices and non-injectable insulin. Now, there’s evidence that the former may have killed off the latter. According to a Fierce Biotech report, Novo Nordisk announced in an October 31st earnings call that it is halting research and development efforts aimed at creating […]
With the surprising announcement this month that the FDA had cleared the way for Medtronic’s 670G hybrid system, sometimes referred to as an artificial pancreas, most people with diabetes were swinging their pump tubing with glee or juggling their (safety-capped) syringes in delight. And with good reason. We are on the cusp of a flood […]
Donald Trump’s electoral college win has already had a ripple effect within diabetes care circles. As he’s been putting together an administration, it’s still been hard to predict where his administration will land on issues that affect people with diabetes. Less than a week after the election, already his positions on health care and health […]
Vermont Senator Bernie Sanders and Maryland Representative Elijah Cummings have sent a letter asking the U.S. Department of Justice and the U.S. Federal Trade Commission to open an investigation into whether the three major insulin-manufacturers “have colluded or engaged in anticompetitive behavior in setting their drug prices.”
John Higgins, M.D., associate professor of systems biology at Harvard Medical School in Boston, along with Dr. Roy Malka and David M. Nathan used an algorithm to analyze blood glucose levels through HbA1c testing. “This enabled the scientists to account for variations in the age of blood cells among different people,” Higgins told Diabetes in […]
On Oct. 11, the regulatory agency issued two sets of guidance, laying out new standards for meters used in clinical settings and also for personal home-use meters. They officially took effect that same day. These guidelines have been many years in the making. The patient and healthcare communities have been voicing concerns about inaccuracy for […]